Last reviewed · How we verify
Metformin and FSHr
This combination uses metformin to improve insulin sensitivity and metabolic parameters while FSHr (follicle-stimulating hormone receptor) agonism promotes follicular development for fertility enhancement.
This combination uses metformin to improve insulin sensitivity and metabolic parameters while FSH receptor stimulation promotes follicle development for fertility enhancement. Used for Polycystic ovary syndrome (PCOS) with infertility, Female infertility with metabolic dysfunction.
At a glance
| Generic name | Metformin and FSHr |
|---|---|
| Also known as | treatment for infertility |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Combination therapy: biguanide + gonadotropin receptor agonist |
| Target | Metformin: mitochondrial glycerophosphate dehydrogenase; FSHr: follicle-stimulating hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive endocrinology / Fertility / Metabolic disorders |
| Phase | FDA-approved |
Mechanism of action
Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity, which can benefit women with insulin resistance and polycystic ovary syndrome (PCOS). FSHr agonism directly stimulates follicle-stimulating hormone receptors on ovarian granulosa cells to promote follicular growth and oocyte maturation. The combination addresses both metabolic dysfunction and ovulatory dysfunction in infertile women.
Approved indications
- Infertility in women with PCOS or insulin resistance
Common side effects
- Gastrointestinal disturbance (metformin)
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reaction (FSHr)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin and FSHr CI brief — competitive landscape report
- Metformin and FSHr updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI